Does radiopaque cement conceal periprosthetic bone loss around femoral stems?
| Autor: | Flatøy B; Division of Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway.; University of Oslo, Oslo, Norway., Dahl J; Division of Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway., Röhrl SM; Division of Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway., Nordsletten L; Division of Orthopaedic Surgery, Oslo University Hospital, Oslo, Norway.; University of Oslo, Oslo, Norway. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Hip international : the journal of clinical and experimental research on hip pathology and therapy [Hip Int] 2020 Nov; Vol. 30 (6), pp. 731-738. Date of Electronic Publication: 2019 Jul 30. |
| DOI: | 10.1177/1120700019863352 |
| Abstrakt: | Background: Periprosthetic bone remodelling may increase fracture risk and deplete bone stock around hip implants. These changes are in part caused by implant design, advocating an early evaluation of bone remodelling properties of new implants. This can be done by repeated dual-energy x-ray absorptiometry (DXA) measurements. We know that radiopaque cement falsely elevates bone mineral density (BMD) in single measurements, however, its impact on repeated measurements, i.e. BMD changes is unexplored. We have therefore investigated whether the presence of radiopaque cement affect repeated BMD measurements. Methods: 33 patients eligible for total hip replacement were randomly assigned to either radiopaque or radiolucent cement. BMD changes up to 12 months were measured by DXA, in addition to Harris Hip Score, plain radiographs and radiostereometric analysis (RSA). Results: Periprosthetic BMD declined during the first 3-6 months in all zones in both groups. The greatest reduction (14%) was seen in the proximal Gruen zones (1 and 7). We found a significant difference in Gruen zones 1 and 2, where the measured bone loss was higher in the radiolucent cement group. Conclusions: The presence of radiopaque agents in bone cement may influence DXA measurements of bone remodelling.ClinicalTrials.gov identifier NCT00473421. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|